Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $158

Truist Securities analyst Gregory Renza has maintained a Buy rating on Gilead Sciences (NASDAQ: GILD) and increased the price target from $150 to $158. This adjustment reflects positive sentiment towards the company's performance and future prospects.